Your browser doesn't support javascript.
loading
Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.
Coutant, D E; Kulanthaivel, P; Turner, P K; Bell, R L; Baldwin, J; Wijayawardana, S R; Pitou, C; Hall, S D.
Afiliação
  • Coutant DE; Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Kulanthaivel P; Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Turner PK; Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Bell RL; Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Baldwin J; Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Wijayawardana SR; Department of Statistics-Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Pitou C; Pharmacokinetics and Pharmacodynamics, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Hall SD; Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA.
Clin Pharmacol Ther ; 98(1): 76-86, 2015 Jul.
Article em En | MEDLINE | ID: mdl-25808023

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Clin Pharmacol Ther Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos